Lipocine Starts Phase 3 BLOOM Trial for Postpartum Depression
Salt Lake City, Utah, United States, November 10, 2026 Lipocine Inc., a specialty pharmaceutical company focused on developing innovative...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Salt Lake City, Utah, United States, November 10, 2026 Lipocine Inc., a specialty pharmaceutical company focused on developing innovative...
CAMBRIDGE, Mass. and COPENHAGEN, Denmark — September 17, 2026 Hemab Therapeutics announced that the first healthy volunteer has been...
VANCOUVER, British Columbia — September 16, 2026 AbCellera announced that it will present Phase 2 efficacy and safety data...
Jersey City, New Jersey, September 15, 2026 Organon has announced that the U.S. Food and Drug Administration (FDA) has...
SHANGHAI, China, Aug 28, 2026 Asieris Pharmaceuticals has released its 2026 Semi-Annual Report, highlighting progress in commercial operations, international...
Ramat Gan, Israel, August 19, 2026 Pulsenmore Ltd. announced the expansion of its home ultrasound activities in Israel following...
RAMAT GAN, Israel — August 17, 2026 Pulsenmore Ltd. has received a $1.27 million grant from the Israel Innovation...
SAN DIEGO, Aug. 13, 2026 Daré Bioscience, Inc. reported its second-quarter 2026 financial results and highlighted significant progress in...
VANCOUVER, British Columbia, August 10, 2026 AbCellera Biologics Inc. announced positive topline results from the Phase 2 portion of...
VANCOUVER, British Columbia, August 7, 2026 AbCellera announced that it will release top-line results from the Phase 2 clinical...
